Novo Nordisk affirms 25% weight-loss expectation for experimental drug CagriSema
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25% weight loss.
Novo’s New Obesity Drug Is Targeting the Most Dramatic Weight Loss Yet
The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a red-hot market hinges on it.
A new weight loss drug could beat Ozempic's side effect problem
The Denmark-based drug maker Zealand Pharma said Tuesday that its experimental weight-loss drug could help patients lose pounds with fewer side effects than current anti-obesity medications on the market.
Novo Nordisk aware of reports 10 people taking compounded weight-loss drug copies died
Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and 100 hospitalisations of people who had taken compounded copies of its weight-loss and diabetes drugs.
Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs
These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates appetite and digestion. The medications control blood sugar and help people eat less,
Teenagers Are Taking New Weight-Loss Drugs, but the Science Is Far from Settled
Wegovy and similar weight-loss medications are becoming widely prescribed for teenagers with obesity, but little is known about their long-term effects
Can new weight loss drugs delay ageing?
What is ageing? Ageing is a highly complex biological process. Our DNA is constantly being broken down and repaired. An imbalance in this process, leading to poor repair of DNA, is one of the hallmarks of ageing.
Map Shows States Where Weight Loss Drugs are Most Popular
Kentucky, Alaska and Alabama are the three states where weight loss drugs are most used, and Hawaii, Arizona and Colorado sit at the other end of the spectrum, a report has revealed.
Novo Nordisk is aware of 10 deaths from compounded weight-loss drug copies
Novo Nordisk is aware of 100 hospitalizations and 10 deaths resulting from people taking compounded copies of its popular weight-loss and diabetes drugs, the drugmaker's finance chief said on Wednesday.
Obesity drug maker Novo Nordisk posts strong profit
Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted Wednesday strong third-quarter earnings despite being held back by production constraints.
Novo Nordisk Posts Solid Earnings. Weight-Loss Drug Wegovy Sales Beat Estimates.
When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated the market for the new GLP-1 weight-loss medicines. W
Nature2d
How ‘miracle’ weight-loss drugs will change the world
These are just some of the ways in which analysts forecast that the new wave of incredibly effective weight-loss ...
Hosted on MSN2d
A new weight loss pill outperformed Novo Nordisk's version
Viking Therapeutics (VKTX) released new clinical trial data on Sunday for its experimental weight-loss drugs, which ...
Microdosing Ozempic? Why some people are playing doctor with weight-loss drugs
The weight-loss drug users and doctors whom The Times spoke to for this ... As powerful anti-obesity drugs become ...
Analysis-Americans Hungry for Weight-Loss Drugs Grapple With Supply and Insurance Hurdles
In interviews with Reuters, eight U.S. obesity specialists at universities and large health systems described a different ...
News Medical on MSN2d
Weight loss drug semaglutide may offer relief for knee arthritis pain
Semaglutide shows promise in treating knee osteoarthritis by reducing pain and weight, offering a safe alternative to traditional pharmacological interventions.
As Race To Best 'Miracle' Obesity Drug Heats Up, Ozempic Maker Novo Nordisk Tests New Hybrid Drug That Can Reduce Weight Up To 25%
Novo's development chief, Martin Holst Lange, has shown optimism about the drug's promise, though he refrained from making ...